Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts give Genmab a consensus recommendation of Moderate Buy from 12 analysts (3 hold, 7 buy, 2 strong buy) with an average 1‑year price target of $39.07.
• Genmab reported quarterly EPS of $0.05, missing estimates of $0.46 while revenue matched $1.06 billion, reflecting an earnings shortfall despite stable sales.
• Large institutional investors have been increasing positions—examples include Orbis Allan Gray (+30.2% to 14.42M shares) and Paradigm Biocapital (+84.4% to 7.04M shares)—indicating notable hedge fund buying interest.

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $39.0714.

A number of brokerages recently issued reports on GMAB. Wolfe Research began coverage on shares of Genmab A/S in a research note on Friday, March 27th. They issued an "outperform" rating and a $32.00 price target for the company. Jefferies Financial Group began coverage on shares of Genmab A/S in a research note on Tuesday, February 17th. They issued a "buy" rating and a $41.50 price target for the company. HC Wainwright dropped their price target on shares of Genmab A/S from $40.00 to $38.00 and set a "buy" rating for the company in a research note on Thursday. Wall Street Zen downgraded shares of Genmab A/S from a "buy" rating to a "hold" rating in a report on Saturday, February 7th. Finally, Morgan Stanley began coverage on shares of Genmab A/S in a report on Monday, February 16th. They issued an "equal weight" rating and a $34.00 price objective for the company.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $26.45 on Monday. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86. The company has a fifty day simple moving average of $27.43 and a 200 day simple moving average of $30.03. The firm has a market cap of $16.49 billion, a PE ratio of 17.06, a price-to-earnings-growth ratio of 1.18 and a beta of 0.86. Genmab A/S has a 12-month low of $18.89 and a 12-month high of $35.43.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 18th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.46 by ($0.41). The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. On average, equities research analysts anticipate that Genmab A/S will post 1.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently added to or reduced their stakes in the business. Orbis Allan Gray Ltd boosted its holdings in Genmab A/S by 30.2% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company's stock worth $444,089,000 after purchasing an additional 3,340,456 shares during the period. Alliancebernstein L.P. boosted its holdings in Genmab A/S by 2.7% in the third quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company's stock worth $335,957,000 after purchasing an additional 291,538 shares during the period. Paradigm Biocapital Advisors LP boosted its holdings in Genmab A/S by 84.4% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company's stock worth $216,827,000 after purchasing an additional 3,222,983 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Genmab A/S by 36.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company's stock worth $153,324,000 after purchasing an additional 1,334,919 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Genmab A/S by 23.8% in the fourth quarter. Renaissance Technologies LLC now owns 3,492,850 shares of the company's stock worth $107,580,000 after purchasing an additional 671,307 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.